Protein Summary
Binds to the 3' poly(U) terminus of nascent RNA polymerase III transcripts, protecting them from exonuclease digestion and facilitating their folding and maturation (PubMed:3192525, PubMed:2470590). In case of Coxsackievirus B3 infection, binds to the viral internal ribosome entry site (IRES) and stimulates the IRES-mediated translation (PubMed:12384597). The protein encoded by this gene is involved in diverse aspects of RNA metabolism, including binding and protecting poly(U) termini of nascent RNA polymerase III transcripts from exonuclease digestion, processing 5' and 3' ends of pre-tRNA precursors, acting as an RNA chaperone, and binding viral RNAs associated with hepatitis C virus. Autoantibodies reacting with this protein are found in the sera of patients with Sjogren syndrome and systemic lupus erythematosus. Alternative promoter usage results in two different transcript variants which encode the same protein. [provided by RefSeq, Jun 2014]
- ENST00000260956
- ENSP00000260956
- ENSG00000138385
- ENST00000409333
- ENSP00000386636
- La
- LARP3
- La/SSB
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
interacting protein | 1 | ||
ligand (protein) perturbation | 0.96 | ||
co-expressed gene | 0.94 | ||
hub protein | 0.92 | ||
protein domain | 0.85 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 457.77 (req: < 5)
Gene RIFs: 79 (req: <= 3)
Antibodies: 480 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 457.77 (req: >= 5)
Gene RIFs: 79 (req: > 3)
Antibodies: 480 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0